Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-09-26
1997-10-21
Fan, Jane
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546193, 546194, A61K 31445, C07D40112
Patent
active
056796927
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to bis-aryl carbinol derivatives, pharmaceutical compositions and methods of using such derivatives.
European Patent Application Publication Number 0235463, published Sep. 9, 1987 discloses compounds of the formula: ##STR4## wherein: Ar, D, and R can be selected from, amongst others, phenyl, substituted phenyl, pyridinyl, thienyl or furanyl; A can be, amongst others, --O--R.sup.1 wherein R.sup.1 can be, amongst others, hydrogen; Q can be absent because n can be zero; p can be one; m is 0 to 6 and can therefore be one; and B can be absent because z can be zero.
International Publication Number WO 89/10369 discloses compounds of the formula: ##STR5## wherein: one of a, b, c and d represents nitrogen or --NR.sup.11 --, wherein R.sup.11 is, amongst others, O.sup.-, and the remaining a, b, c and d groups are CH; T represents carbon or nitrogen, with the dotted line attached to T representing an optional double bond when T is carbon; when m plus n equals 1 or 2, X represents, amongst others, --O-- or --S(O).sub.e -- wherein e is 0, 1 or 2; when m plus n represents 0, X can be, amongst others, any substituent for m plus n equalling 1 or a direct bond; when m plus n equals 3 then X equals a direct bond; Z represents .dbd.O or .dbd.S such that when Z is O, R may be, amongst others, ##STR6## wherein Y is N or NR.sup.11 ; when Z represents .dbd.S, R represents in addition to the R group above, aryloxy or alkoxy.
U.S. Pat. No. 4,826,853 issued to Piwinski et al. on May 2, 1989 is the priority document for WO 88/03138 which published on May 5, 1988. WO 88/03138 discloses compounds of the formula ##STR7## wherein: one of a, b, c and d represents N or NR.sup.9 where R.sup.9 is, amongst others, O, and the remaining a, b, c and d groups are CH; X represents N or C, which C may contain an optional double bond to carbon atom Z represents O, S or H.sub.2 such that when Z is O, R may be, amongst others, ##STR8## when Z represents S, R represents in addition to the R group above, aryloxy or alkoxy; and when Z represents H.sub.2, R can be, amongst others, ##STR9## These compounds are disclosed as being useful in the treatment of allergy and inflammation.
In particular, WO88/03138 discloses intermediates having the formulas: ##STR10##
During the course of research on the compounds disclosed in WO 88/03138, it was generally found that the compounds having a carbonyl group (Z.dbd.O) attached to the piperidyl, piperidylidenyl or piperazinyl nitrogen atom were much stronger antagonists of platelet activating factor (PAF) than the compounds having a CH.sub.2 group (Z.dbd.H.sub.2) attached thereto.
WO 90/13548 published on Nov. 15, 1990 on PCT/US90/02251 which was filed on Apr. 30, 1990 and claims priority to U.S. application Ser. No. 345,604 filed May 1, 1989 discloses compounds similar in structure to the compounds disclosed in WO 88/03138 with the difference being that the R group represents an N-oxide heterocyclic group of the formula (i), (ii), (iii), or (iv): ##STR11## wherein R.sup.9, R.sup.10, and R.sup.11 can be, amongst other groups, H.
Galantay et al., Journal of Medicinal Chemistry, 1974, Vol. 17, No. 12, pp. 1316 to 1327 discloses oxazole and thiazole analogs of amitriptyline. A disclosed intermediate has the formula: ##STR12##
U.S. Pat. No. 4,659,716 discloses an intermediate of the formula: ##STR13##
PCT/US89/01689, International Publication Number 89/WO 10363. published Nov. 2, 1989, discloses compounds of the formula: ##STR14## wherein T represents .dbd.O or ##STR15## Q represents CH, N or N.fwdarw.O; ring A represents defined heterocyclic aromatic rings (see pp. 3 and 4 for example), U is --H or --OH when the bond between W and the cyclohepta ring is a single bond; W represents C, N or N.fwdarw.O and the dotted line drawn to W from the cyclohepta ring represents an optional double bond when W is C, or is absent when W is N.fwdarw.O; and X can be, amongst others: ##STR16## wherein Z is O or S; R.sup.1 can be, amongst others, H, alkyl, cycloalkyl, aryl, and hete
REFERENCES:
patent: 2739968 (1956-03-01), Sperber et al.
patent: 2898339 (1959-08-01), Wheeler et al.
patent: 3325501 (1967-06-01), Ettinsen
patent: 3326924 (1967-06-01), Villani
patent: 3717647 (1973-02-01), Villani
patent: 3803153 (1974-04-01), Villani
patent: 3803154 (1974-04-01), Drukker
patent: 3922276 (1975-11-01), Duncan, Jr. et al.
patent: 3956296 (1976-05-01), Duncan, Jr. et al.
patent: 3966944 (1976-06-01), Carter
patent: 4032642 (1977-06-01), Duncan, Jr. et al.
patent: 4105849 (1978-08-01), Hamilton et al.
patent: 4282233 (1981-08-01), Villani
patent: 4355036 (1982-10-01), Villani
patent: 4540780 (1985-09-01), Downs
patent: 4609664 (1986-09-01), Hasspacher
patent: 4628095 (1986-12-01), Rorig et al.
patent: 4632925 (1986-12-01), Mullin et al.
patent: 4659716 (1987-04-01), Villani et al.
patent: 4797489 (1989-01-01), Abou-Gharbia et al.
patent: 4826853 (1989-05-01), Piwinski et al.
patent: 4835157 (1989-05-01), Press et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5151423 (1992-09-01), Piwinski et al.
patent: 5166205 (1992-11-01), Cuberes-Altisent et al.
Bickel, Pharmacological Review, vol. 21, No. 4, pp. 325, and 335-336 (1969).
Wade, Jr., Organic Chemistry, p. 349, Prentice-Hall, Inc. (1987).
Villani et al., Journal of Medicinal Chemistry, vol. 15, No. 7, pp. 750-754 (1972).
ARZN. FORSH 36 1311-1314 (1986).
Galantay et al., Journal of Medicinal Chemistry, vol. 17, No. 12, pp. 1316 to 1327, 1974.
Ohtaka et al., Chem. Pharm. Bull., 35(10) 4124-4129 (1987).
Kennis et al., Drug Development Research, 8: 133-140 (1986).
Regnier et al., Eur. J. Med. Chem, 22(1987) 243-250.
Nishikawa et al., J. Med. Chem. 1989, 32, 583-593.
Anagnostopulos, Eur. J. Med. Chem. 24 (1989) 227-232.
Ohtaka et al., Chem. Pharm. Bull, 35(8) 3270-3275 (1987).
Cid et al., Tetrahedron, vol. 44, No. 19, pp. 6197 to 6200 (1988).
Meyer et al., Journal of Medicinal Chemistry, 1989, vol. 32, No. 3, pp. 593-597.
Gubert et al., AZNEIM-FORSCH./Drug Res. 37 (II), Nr. 10 (1987) pp. 1103-1107.
Friary Richard
Piwinski John J.
Wong Jesse K.
Fan Jane
Jeanette Henry C.
Schering Corporation
LandOfFree
Unbridged bis-aryl carbinol derivatives, compositions and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Unbridged bis-aryl carbinol derivatives, compositions and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Unbridged bis-aryl carbinol derivatives, compositions and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1007059